Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07186296 · ClinicalTrials.gov registry record
EXoPERT EMERALD Clinical Study
A clinical trial of Breast Cancer and Lung Cancer, sponsored by EXoPERT.
- Recruiting
- Registry status
- 1,400
- Enrollment target
- 9
- Study locations
NCT07186296: Recruiting study of Breast Cancer and Lung Cancer, sponsored by EXoPERT.
NCT07186296 is a study of Breast Cancer and Lung Cancer that is actively recruiting participants, run by EXoPERT. The registered enrollment target is 1,400 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (50% lower). The trial reports 9 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07186296, a study of Breast Cancer and Lung Cancer, is actively recruiting participants, sponsored by EXoPERT.
- RECRUITING
- Registry status
- 1,400 participants
- Enrollment target
- 9
- Study locations
Study Summary
Invitro diagnostic test for multiple cancer diagnosis for patients with early-stage cancers by analyzing surface-enhanced Ramen spectroscopy (SERS) profiles of extracellular vesicles (EV) using artificial intelligence.
Primary Outcome
Test sufficient samples from 5 cancers to lock an validate algorithm to support future clinical study.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST EXoPred
Study Locations (9)
New York
- Albany Stratton VA Medical Center - Albany
- Bronx Veterans Medical Research Foundation - The Bronx
- VA Hudson Valley Healthcare System - Wappingers Falls
California
- Tibor Rubin VA Medical Center - Long Beach
- City of Hope Duarte Cancer Center - Los Angeles
Kentucky
- Lexington VA Healthcare System - Lexington
- KCTL - Louisville
Hawaii
- University of Hawaii Cancer Center - Honolulu
Maryland
- John Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2025-05-09 |
| Est. Completion | 2026-06-30 |
What NCT07186296 shows while recruiting
NCT07186296 is an observational study that tracks outcomes without assigning an intervention. Its 1,400 participants enrollment target places it among the larger protocols in the corpus, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (50% lower).
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which EXoPred is the first listed.
NCT07186296 lists 9 locations in 5 states (New York, California, Kentucky).
Frequently Asked Questions
What is clinical trial NCT07186296 about?
NCT07186296 is a clinical study titled "EXoPERT EMERALD Clinical Study". Invitro diagnostic test for multiple cancer diagnosis for patients with early-stage cancers by analyzing surface-enhanced Ramen spectroscopy (SERS) profiles of extracellular vesicles (EV) using artificial intelligence.
What is the current status of trial NCT07186296?
This trial is currently recruiting. The enrollment target is 1,400 participants. The study started on 2025-05-09. Estimated completion is 2026-06-30.
What conditions does trial NCT07186296 study?
This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Colon Cancer.
What interventions are being tested in trial NCT07186296?
The interventions under investigation include: EXoPred (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07186296?
This trial is sponsored by EXoPERT, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07186296 being conducted?
This trial has 9 study locations across California, Hawaii, Kentucky, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07186296's enrollment target sits among peer trials
1,400 91st of 1224 higher than 1,133 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02205762 · 1,400 participants · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
- NCT02445222 · 1,400 participants · Phase 3
CAR-T Long Term Follow Up (LTFU) Study
- NCT03145077 · 1,400 participants · NA
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
- NCT04250857 · 1,400 participants
HeartStart FRx Defibrillator Event Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI